Nikol Dibus

Nikol Dibus

Auto-generated profile, based on publicly available information

Nikol Dibus

Turku Bioscience Centre, University of Turku and Åbo Akademi University 1 , 20520 Turku

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 February 2024 in Communications Biology
Verified
Journal Article
Open access
PDF file
TTTereza Turkova
Tereza Turkova
JKJuraj Kokavec
Juraj Kokavec
TZTomas Zikmund
Tomas Zikmund
NDNikol Dibus
Nikol Dibus
KPKristyna Pimkova
Kristyna Pimkova
TSTomas Stopka
Tomas Stopka
The formation of hematopoietic cells relies on the chromatin remodeling activities of ISWI ATPase SMARCA5 (SNF2H) and its complexes. The Smarca5 null and conditional alleles have been used to study its functions in embryonic and organ development in mice. These mouse model phenotypes vary from embryonic lethality of constitutive knockout to less severe phenotypes observed in tissue-specific Smarca5 deletions, e.g., in the hematopoietic system. Here we show that, in a gene dosage-dependent manner, the hypomorphic allele of SMARCA5 (S5tg) can rescue not only the developmental arrest in hematopoiesis in the hCD2iCre model but also the lethal phenotypes associated with constitutive Smarca5 deletion or Vav1iCre-driven conditional knockout in hematopoietic progenitor cells. Interestingly, the latter model also provided evidence for the role of SMARCA5 expression level in hematopoietic stem cells, as the Vav1iCre S5tg animals accumulate stem and progenitor cells. Furthermore, their hematopoietic stem cells exhibited impaired lymphoid lineage entry and differentiation. This observation contrasts with the myeloid lineage which is developing without significant disturbances. Our findings indicate that animals with low expression of SMARCA5 exhibit normal embryonic development with altered lymphoid entry within the hematopoietic stem cell compartment.

27 October 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
AYAnoop Kumar Yadav
Anoop Kumar Yadav
AAAlikhan Abdirov
Alikhan Abdirov
KOKatarina Ondruskova
Katarina Ondruskova
SNSimran Negi
Simran Negi
KJKristina Jamrichova
Kristina Jamrichova
LCLukas Cermak
Lukas Cermak
The minichromosome maintenance (MCM2-7) protein complexes are central drivers of genome duplication. Distinct protein pools, parental and nascent MCMs, and their precise equilibrium are essential to sustain error-free DNA replication. However, the mechanism responsible for generating these pools and maintaining their equilibrium remains largely unexplored. Here, we identified CRL4 DCAF12 as a factor controlling the assembly of nascent MCM complexes. During MCM biogenesis, MCMBP facilitates the assembly and transport of newly synthesized MCM3-7 subcomplexes into the nucleus. Once in the nucleus, the MCM2 subunit must be incorporated into the MCM3-7 subcomplex, while MCMBP needs to be removed. CRL4 DCAF12 facilitates the degradation of MCMBP and thereby regulates the assembly of MCM2-7 complexes. The absence of CRL4 DCAF12 adversely affects the level of chromatin-bound nascent MCMs, resulting in accelerated replication forks and replication stress. Collectively, our findings uncovered the molecular mechanism underlying nascent MCM production essential to counteract genome instability.

1 October 2026 in Disease Models & Mechanisms
Verified
Journal Article
Open access
JVJenna Villman
Jenna Villman
NDNikol Dibus
Nikol Dibus
JHJonas Huhn
Jonas Huhn
AHAnna-Mari Haapanen-Saaristo
Anna-Mari Haapanen-Saaristo
IEIlia Evstafev
Ilia Evstafev
KKKari J. Kurppa
Kari J. Kurppa
Zebrafish models are widely used to study BRAF-mutant melanoma biology. However, long-term treatment of adult fish with small-molecule BRAF inhibitors remains challenging, and pharmacokinetic data to inform rational dosing strategies are largely lacking for most small molecules in zebrafish. Here, we assessed the pharmacokinetics, metabolism and efficacy of continuously tank-water-administered dabrafenib, a BRAF inhibitor, in adult zebrafish. Dabrafenib was rapidly absorbed from tank water, reaching efficacious plasma levels within 1 h, but also showed fast elimination kinetics with a half-life of 1.0 h. Most human metabolites of dabrafenib were detected in zebrafish, suggesting conserved metabolic processes. Continuous tank-water administration achieved therapeutically relevant steady-state dabrafenib plasma levels that inhibited BRAF-driven signaling and produced robust efficacy in vivo in a genetic zebrafish model of BRAF-mutant melanoma without apparent toxicity. Together, these results demonstrate that continuous tank-water administration of dabrafenib is a feasible, efficient and well-tolerated dosing strategy in zebrafish melanoma models, and may facilitate dosing of other small-molecule inhibitors, especially those with a short in vivo half-life in zebrafish.

20 December 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
VOVeera K. Ojala
Veera K. Ojala
SASini Ahonen
Sini Ahonen
ATAura Tuohisto-Kokko
Aura Tuohisto-Kokko
Olaya EspartaOlaya Esparta
Olaya Esparta
PSPeppi Suominen
Peppi Suominen
KKKari J. Kurppa
Kari J. Kurppa
Receptor tyrosine kinase ERBB4 (HER4) is frequently mutated in human cancer, and ERBB4 mutations have been identified in patients relapsing on targeted therapy. Here, we addressed the functional consequences of recurrent cancer-associated ERBB4 mutations that are located at regions important for dimer interactions and/or are paralogous to known oncogenic hotspot mutations in other ERBB genes. Eleven out of 18 analyzed mutations were transforming in cell models, thus suggesting oncogenic potential for more than half of the recurrent ERBB4 mutations. More detailed analyses of the most potent mutations, S303F, E452K and L798R, showed that they are activating, can co-operate with other ERBB receptors and are targetable with clinically available second-generation pan-ERBB inhibitors neratinib, afatinib and dacomitinib. Furthermore, the S303F mutation, together with a previously identified activating ERBB4 mutation, E715K, promoted resistance to third-generation EGFR inhibitor osimertinib in EGFR-mutant lung cancer model in vitro and in vivo . Together, these results are expected to facilitate clinical interpretation of the most recurrent cancer-associated ERBB4 mutations. The findings provide rationale for testing the efficacy of clinically used pan-ERBB inhibitors in patients harboring driver ERBB4 mutations both in the treatment-naïve setting, and upon development of resistance to targeted agents.

21 March 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
NDNikol Dibus
Nikol Dibus
ESEva Salyova
Eva Salyova
KKKarolina Kolarova
Karolina Kolarova
MPMichele Pagano
Michele Pagano
OSOndrej Stepanek
Ondrej Stepanek
LCLukas Cermak
Lukas Cermak
SKP1-CUL1-F-box protein (SCF) ubiquitin ligases are versatile protein complexes that mediate the ubiquitination of substrates, which are recognized by their F-box-domain- containing subunits 1 . One of these substrate receptors is FBXO38. Its gene has been found to be mutated in several families with early-onset distal hereditary motor neuronopathy 2 . SCF FBXO38 ubiquitin ligase controls the stability of ZXDB, a nuclear factor associated with the centromeric chromatin protein CENP-B 3 . Moreover, the loss of FBXO38 results in growth retardation and defect in spermatogenesis characterized by deregulation of the Sertoli cell transcription program and centromere integrity 4 . A report by Meng et al. proposed that SCF FBXO38 regulates the protein levels of the PD-1 inhibitory receptor (also known as CD279, PDCD1) in T cells 5 . Here, we have re-addressed the conclusions by Meng et al. using Fbxo38 KO/KO mice and cell systems. We have found no evidence indicating that FBXO38 controls the abundance and stability of PD-1.

13 October 2025 in bioRxiv
Verified
Preprint
Open access
JVJenna Villman
Jenna Villman
NDNikol Dibus
Nikol Dibus
JHJonas Huhn
Jonas Huhn
AHAnna-Mari Haapanen-Saaristo
Anna-Mari Haapanen-Saaristo
IEIlia Evstafv
Ilia Evstafv
KKKari J. Kurppa
Kari J. Kurppa
Zebrafish models are widely used to study the biology of BRAF-mutant melanoma. However, long-term treatment of adult fish with small molecule BRAF inhibitors is challenging, limiting the usefulness of this model to study treatment-induced effects in melanoma biology. In addition, pharmacokinetic studies on small molecule inhibitors in zebrafish that could inform rational dosing strategies, are largely lacking. Here, we have assessed the pharmacokinetics, metabolism and efficacy of continuous tank water -administered BRAF-inhibitor dabrafenib in adult zebrafish. Our results demonstrate that dabrafenib is quickly absorbed from the tank water, reaching efficacious plasma levels within one hour following treatment, but also shows fast elimination kinetics with a half-life of 1.6 hours. We could detect most of the human metabolites of dabrafenib in zebrafish, suggesting that dabrafenib metabolism in zebrafish follows a similar process as in humans. Continuous tank water -administered dabrafenib led to therapeutically relevant steady-state plasma levels that inhibited the BRAF-driven signaling and growth in zebrafish melanoma cells in vitro , and resulted in robust in vivo efficacy in a genetic zebrafish model of BRAF-mutant melanoma, with no apparent toxicity. Together, our results demonstrate that continuous tank water -administered dabrafenib provides a feasible, efficient, and well-tolerated dosing strategy to study treatment-related effects in zebrafish models of BRAF-mutant melanoma. We expect that tank water-administration may also facilitate the dosing of other small molecule inhibitors, especially those with short in vivo half-life in zebrafish. Highlights: Pharmacokinetic analysis demonstrates fast absorption kinetics and short plasma half-life for tank water -administered dabrafenib in zebrafish Dabrafenib is metabolized in zebrafish following a similar metabolic process as in humans Tank water -administered dabrafenib provides a feasible, efficient, and well-tolerated dosing strategy to study treatment-related effects in zebrafish models of BRAF-mutant melanoma Tank water-administration may facilitate dosing of small molecule inhibitors with short in vivo half-life in zebrafish